Xue Bingjie, Qiao Bokang, Jia Lixin, Chi Jimei, Su Meng, Song Yanlin, Du Jie
Beijing Anzhen Hospital, Capital Medical University, Key Laboratory of Remodeling-Related Cardio-Vascular Diseases, Ministry of Education, Beijing Collaborative Innovation Centre for Cardiovascular Disorders, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Disease, No. 2 Anzhen Road, Chaoyang District, Beijing 100029, China.
Institute for Biological Therapy, Henan Academy of Innovations in Medical Science, Zhengzhou, 451163, China.
Biosensors (Basel). 2025 Apr 5;15(4):233. doi: 10.3390/bios15040233.
Changes in microRNA (miRNA) levels are closely associated with the pathological processes of many diseases. The sensitive and fast detection of miRNAs is critical for diagnosis and prognosis. Here, we report a platform employing CRISPR/Cas12a to recognize and report changes in miRNA levels while avoiding complex multi-thermal cycling procedures. A non-enzyme-dependent hybridization chain reaction (HCR) was used to convert the miRNA signal into double-stranded DNA, which contained a Cas12a activation sequence. The target sequence was amplified simply and isothermally, enabling the test to be executed at a constant temperature of 37 °C. The detection platform had the capacity to measure concentrations down to the picomolar level, and the target miRNA could be distinguished at the nanomolar level. By using photonic crystal microarrays with a stopband-matched emission spectrum of the fluorescent-quencher modified reporter, the fluorescence signal was moderately enhanced to increase the sensitivity. With this enhancement, analyzable fluorescence results were obtained in 15 min. The HCR and Cas12a cleavage processes could be conducted in a single tube by separating the two procedures into the bottom and the cap. We verified the sensitivity and specificity of this one-pot system, and both were comparable to those of the two-step method. Overall, our study produced a fast and sensitive miRNA detection platform based on a CRISPR/Cas12a system and enzyme-free HCR amplification. This platform may serve as a potential solution for miRNA detection in clinical practice.
微小RNA(miRNA)水平的变化与许多疾病的病理过程密切相关。对miRNA进行灵敏且快速的检测对于疾病诊断和预后判断至关重要。在此,我们报道了一个利用CRISPR/Cas12a来识别并报告miRNA水平变化的平台,该平台避免了复杂的多轮热循环程序。一种非酶依赖性杂交链式反应(HCR)被用于将miRNA信号转化为双链DNA,其中包含一个Cas12a激活序列。靶序列通过简单的等温扩增,使得检测能够在37℃的恒定温度下进行。该检测平台能够检测低至皮摩尔水平的浓度,并且能够在纳摩尔水平区分靶miRNA。通过使用具有荧光淬灭修饰报告分子的阻带匹配发射光谱的光子晶体微阵列,荧光信号得到适度增强,从而提高了灵敏度。通过这种增强,在15分钟内获得了可分析的荧光结果。HCR和Cas12a切割过程可以通过将两个步骤分别置于管底和管帽中在单个管中进行。我们验证了这个单管系统的灵敏度和特异性,二者均与两步法相当。总体而言,我们的研究基于CRISPR/Cas12a系统和无酶HCR扩增构建了一个快速且灵敏的miRNA检测平台。该平台可能为临床实践中的miRNA检测提供一种潜在的解决方案。